RxDoctor Payments DataLook up a doctor →

Alan Koterba, MD

Allergy · North Palm Beach, FLNPI 1609994458

Payments from drug & device makers

$367,058in general payments, 2019–2025

Across 624 payments — averaging $588.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$109K
  • Grifols Therapeutics LLC$106K
  • Octapharma USA, Inc.$56K
  • GSK$31K
  • Grifols Biologicals LLC$26K
  • Teva Pharmaceuticals USA, Inc.$14K
  • plus $24K from 35 others
$32,361in research payments, 2019–2025

Across 2 payments — averaging $16,180 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ADMA Biomanufacturing LLC$30K
  • Octapharma USA, Inc.$3K

What the payments were for

  • Consulting fees$3,49521%
  • Travel & lodging$230%
  • Food & beverage$12,58577%
  • Education$2331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$367,058 in reported general payments places this provider in the 90th percentile of 56 allergy providers in Florida.

See all allergy providers in Florida

Medicare billing

Part B allowed, 2024
$306,361
Medicare patients
508
Services billed
8,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab38$156,436
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$97,833
Dupixent SyringeDupilumab17$67,478
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$58,829
NucalaMepolizumab12$51,363
Breo ElliptaFluticasone/Vilanterol28$14,217
Epinephrine39$7,022
Arnuity ElliptaFluticasone Furoate15$4,621
BreynaBudesonide/Formoterol Fumarate11$1,901
Albuterol Sulfate HfaAlbuterol Sulfate32$1,352
Montelukast Sodium108$1,301
Cromolyn Sodium15$1,244
Azelastine Hcl43$1,012
Ipratropium Bromide45$936
Wixela InhubFluticasone Propion/Salmeterol14$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta$31,393$129,030125 claims
CSL BehringPrivigen$109,480$97,83326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 allergy providers in Florida.

Other allergy in North Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →